Literature DB >> 22959826

Diagnostic performance of whole brain volume perfusion CT in intra-axial brain tumors: preoperative classification accuracy and histopathologic correlation.

Argyro Xyda1, Ulrike Haberland, Ernst Klotz, Klaus Jung, Hans Christoph Bock, Ramona Schramm, Michael Knauth, Peter Schramm.   

Abstract

BACKGROUND: To evaluate the preoperative diagnostic power and classification accuracy of perfusion parameters derived from whole brain volume perfusion CT (VPCT) in patients with cerebral tumors.
METHODS: Sixty-three patients (31 male, 32 female; mean age 55.6 ± 13.9 years), with MRI findings suspected of cerebral lesions, underwent VPCT. Two readers independently evaluated VPCT data. Volumes of interest (VOIs) were marked circumscript around the tumor according to maximum intensity projection volumes, and then mapped automatically onto the cerebral blood volume (CBV), flow (CBF) and permeability Ktrans perfusion datasets. A second VOI was placed in the contra lateral cortex, as control. Correlations among perfusion values, tumor grade, cerebral hemisphere and VOIs were evaluated. Moreover, the diagnostic power of VPCT parameters, by means of positive and negative predictive value, was analyzed.
RESULTS: Our cohort included 32 high-grade gliomas WHO III/IV, 18 low-grade I/II, 6 primary cerebral lymphomas, 4 metastases and 3 tumor-like lesions. Ktrans demonstrated the highest sensitivity, specificity and positive predictive value, with a cut-off point of 2.21 mL/100mL/min, for both the comparisons between high-grade versus low-grade and low-grade versus primary cerebral lymphomas. However, for the differentiation between high-grade and primary cerebral lymphomas, CBF and CBV proved to have 100% specificity and 100% positive predictive value, identifying preoperatively all the histopathologically proven high-grade gliomas.
CONCLUSION: Volumetric perfusion data enable the hemodynamic assessment of the entire tumor extent and provide a method of preoperative differentiation among intra-axial cerebral tumors with promising diagnostic accuracy.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22959826     DOI: 10.1016/j.ejrad.2012.08.005

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  A semi-automated volumetric software for segmentation and perfusion parameter quantification of brain tumors using 320-row multidetector computed tomography: a validation study.

Authors:  Soo Young Chae; Sangil Suh; Inseon Ryoo; Arim Park; Kyoung Jin Noh; Hackjoon Shim; Hae Young Seol
Journal:  Neuroradiology       Date:  2017-03-24       Impact factor: 2.804

2.  Assessment of brain tumors by magnetic resonance dynamic susceptibility contrast perfusion-weighted imaging and computed tomography perfusion: a comparison study.

Authors:  Elisa Scola; Ilaria Desideri; Andrea Bianchi; Davide Gadda; Giorgio Busto; Alessandro Fiorenza; Tommaso Amadori; Sara Mancini; Vittorio Miele; Enrico Fainardi
Journal:  Radiol Med       Date:  2022-04-20       Impact factor: 6.313

3.  Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time.

Authors:  Takashi Abe; Yoshifumi Mizobuchi; Kohei Nakajima; Yoichi Otomi; Saho Irahara; Yuki Obama; Mungunkhuyag Majigsuren; Delgerdalai Khashbat; Teruyoshi Kageji; Shinji Nagahiro; Masafumi Harada
Journal:  Springerplus       Date:  2015-02-24

Review 4.  MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.

Authors:  Domenico Aquino; Andrea Gioppo; Gaetano Finocchiaro; Maria Grazia Bruzzone; Valeria Cuccarini
Journal:  J Immunol Res       Date:  2017-04-20       Impact factor: 4.818

Review 5.  Hemodynamic Imaging in Cerebral Diffuse Glioma-Part A: Concept, Differential Diagnosis and Tumor Grading.

Authors:  Lelio Guida; Vittorio Stumpo; Jacopo Bellomo; Christiaan Hendrik Bas van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.